Literature DB >> 21446974

Chronic calcineurin inhibitor nephrotoxicity-lest we forget.

J R Chapman1.   

Abstract

Calcineurin inhibitor (CNI) nephrotoxicity was recognized in Cambridge in the late 1970s. The vasoconstrictor impact of cyclosporine (CsA) and to a lesser extent tacrolimus, in both acute and chronic settings, results from a decrease in vasodilators and increase in vasconconstrictors while direct tubular toxicity results from blockade of mitochondrial permeability transition pores and inhibition of prolyl isomerase. A biopsy of native kidneys of recipients of CNIs reveals nephrotoxicity as the most common pathological diagnosis with chronic CNI toxicity and hypertension the primary problems. A long-term study of randomized clinical trials with up to 20 years of follow-up shows inferiority of both renal function and graft survival for continuous CsA compared to either CsA withdrawal or continuous azathioprine and prednisolone. Pathological hallmarks of chronic CNI nephrotoxicity include stripped interstitial fibrosis, arteriolar hyalinosis and glomerular sclerosis, but with the exception of nodular arteriolar hyalinosis the findings are non specific. The model for chronic renal allograft loss must be multifactorial with both immune and nonimmune factors operating dependent upon an individual's risk factors for cell and/or antibody-mediated rejection, CNI nephrotoxicity and recurrent disease. Better outcomes will require early diagnosis and individualization of therapy dependent upon the dominant mechanisms impacting each patient. The revisionist view put forward by some senior, experienced and thoughtful individuals, challenges the concept of chronic CNI nephrotoxicity as an important clinical entity. By implication, the view that appears to be promoted is as follows: we need not fear-prolonged exposure to CNIs, and in seeking better long-term solutions for transplant recipients, we have forgotten alloimmunity. It is thus apparent that we must revisit the data and again question the basis for chronic CNI nephrotoxicity in current clinical practice. This contribution to the debate will focus on the evidence that CNIs are nephrotoxic and that their impact needs to be limited if we are to improve long-term outcomes after transplantation, leaving others to promote the contrary perspective and perhaps also to reflect on the largely unproven impact of the steroid avoidance and other minimization strategies so prevalent today. ©2011 The Author Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446974     DOI: 10.1111/j.1600-6143.2011.03504.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  36 in total

Review 1.  Is it time to give up with calcineurin inhibitors in kidney transplantation?

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2013-06-24

2.  N-Octanoyl dopamine transiently inhibits T cell proliferation via G1 cell-cycle arrest and inhibition of redox-dependent transcription factors.

Authors:  Johannes Wedel; Maximillia C Hottenrott; Eleni Stamellou; Annette Breedijk; Charalambos Tsagogiorgas; Jan-Luuk Hillebrands; Benito A Yard
Journal:  J Leukoc Biol       Date:  2014-06-13       Impact factor: 4.962

3.  Kidney involvement in psoriasis: a case-control study from China.

Authors:  Fang Ren; Min Zhang; Liying Hao; Hong Sang
Journal:  Int Urol Nephrol       Date:  2017-09-22       Impact factor: 2.370

Review 4.  Clinical role of the renal transplant biopsy.

Authors:  Winfred W Williams; Diana Taheri; Nina Tolkoff-Rubin; Robert B Colvin
Journal:  Nat Rev Nephrol       Date:  2012-01-10       Impact factor: 28.314

5.  Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A.

Authors:  J Furuzawa-Carballeda; G Lima; J Alberú; D Palafox; N Uribe-Uribe; L E Morales-Buenrostro; R Reyes Acevedo; G Mondragón; A Chevaile; L Llorente
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

6.  The spectrum of renal abnormalities in patients with psoriasis.

Authors:  Erkan Dervisoglu; Aysun Sikar Akturk; Kursat Yildiz; Rebiay Kiran; Ahmet Yilmaz
Journal:  Int Urol Nephrol       Date:  2011-04-20       Impact factor: 2.370

7.  Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.

Authors:  Julio Pascual; Stefan P Berger; Oliver Witzke; Helio Tedesco; Shamkant Mulgaonkar; Yasir Qazi; Steven Chadban; Federico Oppenheimer; Claudia Sommerer; Rainer Oberbauer; Yoshihiko Watarai; Christophe Legendre; Franco Citterio; Mitchell Henry; Titte R Srinivas; Wen-Lin Luo; AnaMaria Marti; Peter Bernhardt; Flavio Vincenti
Journal:  J Am Soc Nephrol       Date:  2018-05-11       Impact factor: 10.121

8.  Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation.

Authors:  Craig B Woda; Sarah Bruneau; Anne Linde Mak; Zdenka Haskova; Kaifeng Liu; Chandra C Ghosh; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2019-09-18       Impact factor: 3.575

Review 9.  Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection.

Authors:  Ying-Chun Lo; Chen-Fang Lee; Jonathan D Powell
Journal:  Curr Opin Organ Transplant       Date:  2014-08       Impact factor: 2.640

Review 10.  Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.

Authors:  Andrew Scott Mathis; Gwen Egloff; Hoytin Lee Ghin
Journal:  World J Transplant       Date:  2014-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.